Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ID110521156
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Ildong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : ID110521156
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Ildong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ID110521156
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Yunovia Gets MFDS Approval for Phase 1 MAD Study of GLP-1 Agonist
Details : ID110521156 is an orally available small molecule agonist of the GLP-1 receptor. It is being developed for the treatment of obesity and diabetes
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2024
Lead Product(s) : ID110521156
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ID110521156
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Ildong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2023
Lead Product(s) : ID110521156
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Ildong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable